The FDA’s re-review of Vanda Pharmaceuticals’ jet lag treatment Hetlioz has resulted in a rejection, the latest twist in a yearslong dispute.
Vanda said Thursday that the agency determined its clinical …
Read More from Endpoints News
FDA rejects Vanda’s jet lag drug following yearslong dispute
